Medical Advocates

Abacavir/Lamivudine
(Epzicom/Kivexa)
 
Main Page

New and Noteworthy 
Journal Citations
Conference Citations






 


ARV Drugs Main Page Main New/Newsworthy   Home Page    

Last Updated:  April 19, 2017
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

New and Noteworthy
     

April  2017
 
 

Journal Abstracts, Papers, Commentaries
     

 
Bone density, microarchitecture and tissue quality following long-term treatment with tenofovir/emtricitabine or abacavir/lamivudine.
Güerri-Fernández R, Molina-Morant D, et al 
J Acquir Immune Defic Syndr
. 2017 Apr 7.
Abstract

Evaluation of the Lipid Concentrations after Switching from Antiretroviral Drug Tenofovir Disoproxil Fumarate/Emtricitabine to Abacavir Sulfate/Lamivudine in Virologically-suppressed Human Immunodeficiency Virus-infected Patients.
Arae H, Tateyama M, Nakamura H,  
Intern Med. 2016;55(23):3435-3440
Abstract

FULL-TEXT ARTICLE
Abacavir/Lamivudine plus Rilpivirine Is an Effective and Safe Strategy for HIV-1 Suppressed Patients: 48 Week Results of the SIMRIKI Retrospective Study.
Troya J, Ryan P, Ribera E, et al
PLoS One. 2016 Oct 11;11(10):e0164455.

Paper

Long-term efficacy and toxicity of abacavir/lamivudine/nevirapine compared to the most prescribed ARV regimens before 2013 in a French Nationwide Cohort Study.
de Boissieu P, Dramé M, Raffi F, et al
Medicine (Baltimore). 2016 Sep;95(37):e4890.
Abstract

Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patients.
Curran A, Rojas J, Cabello A, Troya J, et al
J Antimicrob Chemother
. 2016 Sep 2.
Abstract

Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice.
Lackey P, Mills A, Carpio F, et al
Clin Drug Investig. 2016 Sep 1.
Abstract

Exploratory Analysis for the Evaluation of Estimated Glomerular Filtration Rate, Cholesterol and Triglycerides after Switching from Tenofovir/Emtricitabine plus Atazanavir/Ritonavir (ATV/r) to Abacavir/Lamivudine plus ATV/r in Patients with Preserved Renal Function.
Postorino MC, Quiros-Roldan E, Maggiolo F, et al
Open AIDS J
. 2016 Jul 15;10:136-43.
Abstract

FULL-TEXT ARTICLE
An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy.
M Llibre J, Raffi F, Moyle G, et al
PLoS One
. 2016 May 19;11(5):e0155406.
Paper

Comparative risk of failure of ABC/3TC or TDF/FTC based first-line regimens in patients with a high viral load.
Flandre P, Pugliese P, Allavena C,  et al 
HIV Med. 2016 May;17(5):380-4.
Abstract

Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz.
Calza L, Magistrelli E, Danese I,   et al
Curr HIV Res. 2016;14(1):61-70.
Abstract

Backbone switch to abacavir/lamivudine fixed-dose combination: implications for antiretroviral therapy optimization.
Fantauzzi A, Floridia M, Falasca F, et al
New Microbiol
. 2015 Oct 20;38(4).
Abstract

Abacavir/Dolutegravir/Lamivudine Single-Tablet Regimen: A Review of Its Use in HIV-1 Infection.
Greig SL, Deeks ED.
Drugs
. 2015 Feb 20.
Abstract

FULL-TEXT ARTICLE
A Randomized Comparative Trial of Continued Abacavir/Lamivudine plus Efavirenz or Replacement with Efavirenz/Emtricitabine/Tenofovir DF in Hypercholesterolemic HIV-1 Infected Individuals.
Moyle GJ, Orkin C, Fisher M,  et al
PLoS One
. 2015 Feb 6;10(2):e0116297.

Paper

Correction: Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial.
PLOS ONE Staff.
PLoS One
. 2014 Jul 23;9(7):e103925.

Abstract

Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: a multicentre experience in antiretroviral therapy-naive and -experienced patients.
Podzamczer D, Imaz A, Perez I, et al
J Antimicrob Chemother
. 2014 May 15.
Abstract

FULL-TEXT ARTICLE
Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial.

Wohl DA, Bhatti L, Small CB,  et al
PLoS One. 2014 May 13;9(5):e96187.
Paper

Safety analysis of Epzicom® (lamivudine/abacavir sulfate) in post-marketing surveillance in Japan.
Kurita T, Kitaichi T, Nagao T,  et al
Pharmacoepidemiol Drug Saf. 2014 Mar 3.
Abstract

Early Virologic Response to Abacavir/Lamivudine and Tenofovir/Emtricitabine During ACTG A5202.
Grant PM, Tierney C, Budhathoki C,  et al
HIV Clin Trials
. 2013 Nov-Dec;14(6):284-91.
Abstract

96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle GJ, Stellbrink HJ, Compston J, et al
Antivir Ther
. 2013 Jul 31.

Abstract

Pharmacokinetic interactions between lersivirine and zidovudine, tenofovir disoproxil fumarate/emtricitabine and abacavir/lamivudine.
Vourvahis M, Davis J, Langdon G,  et al
Antivir Ther. 2013 Apr 4.
Abstract

Once-daily darunavir/ritonavir and abacavir/lamivudine versus tenofovir/emtricitabine for treatment-naïve patients with a baseline viral load of more than 100 000 copies/ml.
Nishijima T, Komatsu H, Teruya K,  et al
AIDS. 2013 Mar 13;27(5):839-42
Abstract

Abacavir/Lamivudine versus Tenofovir/Emtricitabine with Atazanavir/Ritonavir for Treatment-naive Japanese Patients
with HIV-1 Infection: A Randomized Multicenter Trial.
Nishijima T, Takano M, Ishisaka M,  et al
|Intern Med. 2013;52(7):735-44
Abstract

Novel Kivexa-based regimens in early courses of treatment for HIV infection.
Conway B, Alenezi O, Wong L,  et al
J Int AIDS Soc. 2012 Nov 11;15(6):18283.
Abstract

Effectiveness and tolerability of abacavir-lamivudine-nevirapine (ABC/3TC/NVP) in a multicenter cohort of HIV-infected ARV-experienced patients.
Podzamczer D, Ferrer E, Llibre J, et al
J Int AIDS Soc
. 2
012 Nov 11;15(6):18343

Abstract

Changes in Fat Mitochondrial DNA and Function in Subjects Randomized to Abacavir/Lamivudine or Tenofovir DF/Emtricitabine with Atazanavir/Ritonavir or Efavirenz: AIDS Clinical Trials Group Study A5224s, substudy of A5202.
McComsey GA, Daar ES, O'Riordan , et al
J Infect Dis. 2012 Nov 29.
Abstract

Abacavir/lamivudine vs tenofovir/emtricitabine in virologically suppressed patients switching from ritonavir-boosted protease inhibitors to raltegravir.
Martinez E, D'Albuquerque PM, Perez I,  et al
AIDS Res Hum Retroviruses
. 2012 Aug 23
Abstract

FULL-TEXT ARTICLE
Changes in Bone Turnover and Bone Loss in HIV-Infected Patients Changing Treatment to Tenofovir-Emtricitabine or Abacavir-Lamivudine.
Haskelberg H, Hoy JF, Amin J, et al
PLoS One. 2012;7(6):e38377
Paper

Inflammation markers after randomization to abacavir/lamivudine or tenofovir/emtricitabine with efavirenz or
atazanavir/ritonavir: ACTG A5224 s, A5202 substudy.
McComsey GA, Kitch D, Daar ES, et al
AIDS
. 2012 Apr 26
Abstract

Effects of highly active antiretroviral therapy on platelet activating factor metabolism in naive HIV-infected patients:
ii) study of the abacavir/lamivudine/efavirenz HAART regimen.
Chini M, Tsoupras AB, Mangafas N, et al
Int J Immunopathol Pharmacol. 2012 Jan-Mar;25(1):247-58.
Abstract

Changes in body composition and mitochondrial DNA in HIV-1-infected patients switching
to fixed-dose abacavir/lamivudine or tenofovir/emtricitabine: a substudy of the BICOMBO Trial.
Curran A, Martinez E, Podzamczer D, et al
Antivir Ther
. 2012 Feb 28. 
Abstract

FULL-TEXT ARTICLE
Predictors of Limb Fat Gain in HIV Positive Patients Following a Change to Tenofovir-Emtricitabine or Abacavir-Lamivudine.
Martin A, Amin J, Emery S,  et al
PLoS One. 2011;6(10):e26885
Paper

Abacavir/Lamivudine Versus Tenofovir DF/Emtricitabine as Part of Combination Regimens for
Initial Treatment of HIV: Final Results.
Sax PE, Tierney C, Collier AC,  et al  
J Infect Dis
. 2011 Oct;204(8):1191-1201.
Abstract

Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Rizzardini G, Zucchi P.
Expert Opin Pharmacother. 2011 Sep;12(13):2129-38
Abstract
Comparison of abacavir/lamiv
udine and tenofovir/emtricitabine among treatment-naïve

HIV-infected patients initiating therapy.
Tan DH, Chan K, Raboud J, Cooper C, et al
J Acquir Immune Defic Syndr
. 2011 Jun 24.
Abstract

Peripheral and Central Fat Changes in Subjects Randomized to Abacavir-Lamivudine or
Tenofovir-Emtricitabine With Atazanavir-Ritonavir or Efavirenz: ACTG Study A5224s.
McComsey GA, Kitch D, Sax PE, et al 
Clin Infect Dis
. 2011 Jul;53(2):185-96.
Abstract

Bone Mineral Density and Fractures in Antiretroviral-Naive Persons Randomized to Receive
Abacavir-Lamivudine or Tenofovir Disoproxil Fumarate-Emtricitabine Along With Efavirenz or
Atazanavir-Ritonavir: AIDS Clinical Trials Group A5224s, a Substudy of ACTG A5202.
McComsey GA, Kitch D, Daar ES,  et al
J Infect Dis. 2011 Jun;203(12):1791-801.
Abstract
 
Open-label randomized multicenter selection study of once daily antiretroviral treatment regimen
comparing ritonavir-boosted atazanavir to efavirenz with fixed-dose abacavir and Lamivudine.
Honda M, Ishisaka M, Ishizuka N,  et al
Intern Med
. 2011;50(7):699-705.
Abstract
 
Pharmacokinetics and acceptability of once- versus twice-daily lamivudine and
abacavir in HIV type-1-infected Ugandan children in the ARROW Trial.
Musiime V, Kendall L, Bakeera-Kitaka S,  et al
Antivir Ther. 2010;15(8):1115-1124.
Abstract
 
Comparison of Changes in Bone Density and Turnover with Abacavir-Lamivudine versus
Tenofovir-Emtricitabine in HIV-Infected Adults: 48-Week Results from the ASSERT Study.
Stellbrink HJ, Orkin C, Arribas JR, et al
Clin Infect Dis. 2010 Sep
Abstract
 
Randomized Comparison of Renal Effects, Efficacy, and Safety With Once-Daily
Abacavir/Lamivudine Versus Tenofovir/Emtricitabine, Administered With Efavirenz,
in Antiretroviral-Naive, HIV-1-Infected Adults: 48-Week Results From the ASSERT
Study.
Post FA, Moyle GJ, Stellbrink HJ,  et al
J Acquir Immune Defic Syndr. 2010 Apr 24
Abstract

Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy.
Sax PE, Tierney C, Collier AC,  et al 
N Engl J Med
. 2009 Dec 3;361(23):2230-2240.
Abstract
 
Abacavir and lamivudine combination.
Somboonwit C, Kurtyka D, Paula Velez A.
Expert Opin Drug Metab Toxicol
. 2009 Dec;5(12):1599-606.

Abstract
 
Simplification of Antiretroviral Therapy with Tenofovir-Emtricitabine or Abacavir-Lamivudine:
A Randomized, 96-Week Trial.
Martin A, Bloch M, Amin J, et al   
Clin Infect Dis
. 2009 Nov 15;49(10):1591-1601

Abstract
 
Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or
tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY, Patel P, Fine D, et al
AIDS 2009 Jun 17.
Abstract
 
Virologic response and safety of the abacavir/lamivudine fixed-dose formulation as part of highly active
antiretroviral therapy: analyses of six clinical studies.
Ha B, Liao QM, Dix LP, Pappa KA.
HIV Clin Trials. 2009 Mar-Apr;10(2):65-75
Abstract|
A Simplification Trial Switching From Nucleoside Reverse Transcriptase Inhibitors to Once-Daily
Fixed-Dose Abacavir/Lamivudine or Tenofovir/Emtricitabine in HIV-1-Infected Patients With Virological
Suppression.

Martínez E, Arranz JA, Podzamczer D, et al
J Acquir Immune Defic Syndr. 2009 Apr 24.
Abstract
 
Two novel fixed formulations of nucleoside analogues (tenofovir-emtricitabine, and
abacavir-lamivudine). Prospective, open study on clinical practice and therapeutic
perspectives, in patients naïve and in subjects pre-treated with antiretrovirals
Manfred R, Calza L.
Recenti Prog Med. 2008 Oct;99(10):492-501
Abstract

Switching from twice-daily abacavir and lamivudine to the once-daily fixed-dose combination tablet of
abacavir and lamivudine improves patient adherence and satisfaction with therapy.

Maitland D, Jackson A, Osorio J, et al 
HIV Med
. 2008 Oct;9(8):667-72.
Abstract

 
Recent Availability of Two Novel, Fixed Formulations of Antiretroviral Nucleoside Analogues:
A 12-Month Prospective, Open-Label Survey of Their Practical Use and Therapeutic Perspectives
in Antiretroviral-Naive and -Experienced Patients.
Manfredi R, Calza L.
AIDS Patient Care
STDS. 2008 Feb 21
Abstract
 
Abacavir/lamivudine combination in the treatment of HIV-1 infection: a review.
Waters L, Moyle G.
Expert Opin Pharmacothe
r. 2006 Dec;7(18):2571-2580.
Abstract
 
Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with
abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced
HIV-1-infected patients (CAL30001 Study).

Lamarca A, Clumeck N, Plettenberg A, et al
J Acquir Immune Defic Syndr. 2006 Apr 15;41(5):598-606.
Abstract
 
Fixed dose combination abacavir/lamivudine in the treatment of HIV-1 infection.
Anderson AM, Bartlett JA. 
Expert Rev Anti Infect Ther. 2005 Dec;3(6):871-83
Abstract
 
Abacavir and Lamivudine Fixed-Dose Combination Tablet Once Daily Compared With Abacavir
and Lamivudine Twice Daily in HIV-Infected Patients Over 48 Weeks (ESS30008, SEAL).
Sosa N, Hill-Zabala C, Dejesus E, et al 
J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):422-427
Abstract
 
Two-once-daily fixed-dose NRTI combinations for HIV.
[
No authors listed]  
Med Lett Drugs Ther
. 2005 Feb 28;47(1203):19-20
Abstract

Abacavir plus Lamivudine: A Review of their Combined Use in the Management of HIV Infection.
Dando TM, Scott LJ. 
Drugs. 2005;65(2):285-302
Abstract


Pediatric Indications
     

  Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
Musiime V, Kasirye P, Naidoo-James B, et al
AIDS. 2016 Apr 8.
Abstract


ARV Drugs Main Page Main New/Newsworthy   Home Page    

Abacavir/Fixed Dose Lamivudine (Epzicom)
Main Page